2025-524487-37-00招募中4 期
Real-World Effectiveness and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy (C3G) or Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN): A Multi-Country Study (PRISMC3)
干预措施
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 入组人数
- 69
- 试验地点
- 70
研究概览
简要总结
To describe the real-world clinical effectiveness of pegcetacoplan in participants with C3G or primary IC-MPGN.
研究设计
- 分配方式
- Na
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 0 years 至 65+ years（65+ Years, 0-17 Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Have received or plan to receive pegcetacoplan for the treatment of C3G or primary IC-MPGN.
- •Provided signed and dated informed consent. For participants under the legal age signed and dated informed consent is provided by the participant’s legally authorised representative. Assent will also be obtained from paediatric participants as required by local regulations.
排除标准
- •Receiving an investigational treatment for C3G or primary IC-MPGN at the time of pegcetacoplan initiation.
- •Initiated treatment with pegcetacoplan in an interventional study.
研究组 & 干预措施
ASPAVELI 1 080 mg solution for infusion, ASPAVELI 1 080 mg solution for infusion
Test
干预措施: ASPAVELI 1 080 mg solution for infusion (Drug)
研究者
Study Physician
Scientific
Swedish Orphan Biovitrum AB (publ)
研究点 (70)
Loading locations...
相似试验
招募中
3 期
A study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis (VALE)2023-504625-39-00Apellis Pharmaceuticals Inc.66
已完成
3 期
A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis2024-514130-20-00Apellis Pharmaceuticals Inc.19
招募中
1 期
An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular CarcinomaAdvanced Hepatocellular Carcinoma (HCC)GPC3 Positive Hepatocellular CarcinomaNCT07493044Guangzhou FineImmune Biotechnology Co., LTD.15
尚未招募
1 期
68Ga-NYM207 PET/CT Imaging in Hepatocellular CarcinomaNCT07590336Peking Union Medical College Hospital100
招募中
1 期
A Study of APG-3288 in Relapsed/Refractory Blood CancersNCT07424833Ascentage Pharma Group Inc.180